Startup Spotlight

Founded in 2022 Pathfinder Bio’s team consists of Dr Gareth Little (CEO, co-founder), an expert in biomanufacturing with 14 years of experience in engineering biology for chemical production, and Professor John Heap (Inventor, co-founder): a research leader within bioengineering and 3x founder. They are joined by Dr Hasan Tanvir Imam (Senior Scientist), an expert in biocatalysis and enzyme development. Pathfinder Bio are currently looking for a co-founder/C-suite level executive with experience within Biomanufacturing to join full-time and help shape the company’s commercial activities and drive impact of their proprietary technology within target markets.

Aonghus Topham

January 6, 2025

The current global mental health crisis puts half of the world at risk of experiencing a mental health disorder in their lifetime. Cambridge Adaptive Testing is addressing this challenge with Artemis-A, an AI-based adaptive testing tool that uses dynamic, personalized questions to precisely measure mental distress within minutes, overcoming inefficiencies of traditional models and enabling early identification of mental health issues.

Shubhi Raghav

December 13, 2024

With a strong founding team and ongoing investment: medtech company Flowmark is set to launch the first of its innovative, affordable devices to simplify fluid management and protect patient safety.

Saira Loane

January 6, 2025

CardiaTec is at the forefront of drug development for cardiovascular diseases. Through sequencing and AI, they are generating the largest multiomics dataset surrounding human hearts to uncover novel therapeutics.

Lucy Ahern

December 13, 2024

Cultivated or cultured meat is an exciting technology that provides an alternative to traditional farmed, animal meat. It has various advantages in environmental impact, animal welfare, and more. Meatly is a start-up producing cultivated, lab-grown meat and what sets them apart is that they specialise in producing pet food.

Sandeep Mangrati

December 13, 2024

Kadence Bio (formerly Kanna Health) is a clinical-stage drug development company pioneering new treatments for sexual health. Their lead asset, KH-001, is being developed as the first FDA-approved treatment for premature ejaculation. The company recently completed a Phase I clinical trial and is planning to initiate Phase II trials next year.

Laura Castillo De Franca

December 13, 2024